APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Chronic Idiopathic Constipation (CIC) Drugs

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Chronic Idiopathic Constipation (CIC) Drugs Market Outlook and Growth Opportunities 2026

Report ID 173977960420 December 2025199 pages

Choose your research edition.

Industry ResearchChronic Idiopathic Constipation (CIC) Drugs Industry Research Report 2026123 pages · $2,950 USDIndustry Growth & TrendsGlobal Chronic Idiopathic Constipation (CIC) Drugs Industry Growth and Trends Forecast to 2032101 pages · $3,450 USDMarket StructureGlobal Chronic Idiopathic Constipation (CIC) Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032194 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Chronic Idiopathic Constipation (CIC) Drugs Market Outlook and Growth Opportunities 2026199 pages · $4,250 USDMarket Analysis & ForecastGlobal Chronic Idiopathic Constipation (CIC) Drugs Market Analysis and Forecast 2026-2032192 pages · $4,950 USD

Market perspective

The global Chronic Idiopathic Constipation (CIC) Drugs market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Chronic Idiopathic Constipation (CIC) Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Chronic Idiopathic Constipation (CIC) Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Chronic Idiopathic Constipation (CIC) Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Chronic Idiopathic Constipation (CIC) Drugs market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Chronic Idiopathic Constipation (CIC) Drugs market include Sanofi, Pfizer, GlaxoSmithKline, Bayer, Synergy Pharmaceuticals, Sucampo Pharmaceuticals, Salix Pharmaceuticals, Roche Holding and Progenics Pharmaceuticals, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Chronic Idiopathic Constipation (CIC) Drugs market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Chronic Idiopathic Constipation (CIC) Drugs and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Chronic Idiopathic Constipation (CIC) Drugs sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Chronic Idiopathic Constipation (CIC) Drugs market size, projected growth trends, production technologies, key applications, and end-use industries.

Chronic Idiopathic Constipation (CIC) Drugs Segment by Company

Sanofi

Pfizer

GlaxoSmithKline

Bayer

Synergy Pharmaceuticals

Sucampo Pharmaceuticals

Salix Pharmaceuticals

Roche Holding

Progenics Pharmaceuticals

Ironwood Pharmaceuticals

Ferring International Center

Chugai Pharmaceutical

Actavis

Chronic Idiopathic Constipation (CIC) Drugs Segment by Type

Lubiprostone

Linaclotide

Others

Chronic Idiopathic Constipation (CIC) Drugs Segment by Application

Ambulatory Surgical Centres

Hospitals & Clinics

Long Term Care Centres

Others

Chronic Idiopathic Constipation (CIC) Drugs Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Chronic Idiopathic Constipation (CIC) Drugs status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Chronic Idiopathic Constipation (CIC) Drugs market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Chronic Idiopathic Constipation (CIC) Drugs significant trends, drivers, influence factors in global and regions.

6. To analyze Chronic Idiopathic Constipation (CIC) Drugs competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Chronic Idiopathic Constipation (CIC) Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Chronic Idiopathic Constipation (CIC) Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Chronic Idiopathic Constipation (CIC) Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Chronic Idiopathic Constipation (CIC) Drugs market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Chronic Idiopathic Constipation (CIC) Drugs industry.

Chapter 3: Detailed analysis of Chronic Idiopathic Constipation (CIC) Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Chronic Idiopathic Constipation (CIC) Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Chronic Idiopathic Constipation (CIC) Drugs in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Chronic Idiopathic Constipation (CIC) Drugs Industry Trends Table 2. Chronic Idiopathic Constipation (CIC) Drugs Industry Drivers Table 3. Chronic Idiopathic Constipation (CIC) Drugs Industry Opportunities and Challenges Table 4. Chronic Idiopathic Constipation (CIC) Drugs Industry Restraints Table 5. Global Chronic Idiopathic Constipation (CIC) Drugs Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Chronic Idiopathic Constipation (CIC) Drugs Revenue Share by Company (2021-2026) Table 7. Global Chronic Idiopathic Constipation (CIC) Drugs Sales Volume by Company (K Units) & (2021-2026) Table 8. Global Chronic Idiopathic Constipation (CIC) Drugs Sales Volume Share by Company (2021-2026) Table 9. Global Chronic Idiopathic Constipation (CIC) Drugs Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Chronic Idiopathic Constipation (CIC) Drugs Company Ranking, (2024-2026) & (USD Million) Table 11. Global Chronic Idiopathic Constipation (CIC) Drugs Key Company Manufacturing Base & Headquarters Table 12. Global Chronic Idiopathic Constipation (CIC) Drugs Company, Product Type & Application Table 13. Global Chronic Idiopathic Constipation (CIC) Drugs Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Chronic Idiopathic Constipation (CIC) Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Lubiprostone Table 18. Significant Companies of Linaclotide Table 19. Significant Companies of Others Table 20. Global Chronic Idiopathic Constipation (CIC) Drugs Sales Volume by Type 2021 VS 2025 VS 2032 (K Units) Table 21. Global Chronic Idiopathic Constipation (CIC) Drugs Sales Volume by Type (2021-2026) & (K Units) Table 22. Global Chronic Idiopathic Constipation (CIC) Drugs Sales Volume by Type (2027-2032) & (K Units) Table 23. Global Chronic Idiopathic Constipation (CIC) Drugs Sales Volume Share by Type (2021-2026) Table 24. Global Chronic Idiopathic Constipation (CIC) Drugs Sales Volume Share by Type (2027-2032) Table 25. Global Chronic Idiopathic Constipation (CIC) Drugs Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Chronic Idiopathic Constipation (CIC) Drugs Sales Value by Type (2021-2026) & (US$ Million) Table 27. Global Chronic Idiopathic Constipation (CIC) Drugs Sales Value by Type (2027-2032) & (US$ Million) Table 28. Global Chronic Idiopathic Constipation (CIC) Drugs Sales Value Share by Type (2021-2026) Table 29. Global Chronic Idiopathic Constipation (CIC) Drugs Sales Value Share by Type (2027-2032) Table 30. Significant Companies of Ambulatory Surgical Centres Table 31. Significant Companies of Hospitals & Clinics Table 32. Significant Companies of Long Term Care Centres Table 33. Significant Companies of Others Table 34. Global Chronic Idiopathic Constipation (CIC) Drugs Sales Volume by Application 2021 VS 2025 VS 2032 (K Units) Table 35. Global Chronic Idiopathic Constipation (CIC) Drugs Sales Volume by Application (2021-2026) & (K Units) Table 36. Global Chronic Idiopathic Constipation (CIC) Drugs Sales Volume by Application (2027-2032) & (K Units) Table 37. Global Chronic Idiopathic Constipation (CIC) Drugs Sales Volume Share by Application (2021-2026) Table 38. Global Chronic Idiopathic Constipation (CIC) Drugs Sales Volume Share by Application (2027-2032) Table 39. Global Chronic Idiopathic Constipation (CIC) Drugs Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 40. Global Chronic Idiopathic Constipation (CIC) Drugs Sales Value by Application (2021-2026) & (US$ Million) Table 41. Global Chronic Idiopathic Constipation (CIC) Drugs Sales Value by Application (2027-2032) & (US$ Million) Table 42. Global Chronic Idiopathic Constipation (CIC) Drugs Sales Value Share by Application (2021-2026) Table 43. Global Chronic Idiopathic Constipation (CIC) Drugs Sales Value Share by Application (2027-2032) Table 44. Global Chronic Idiopathic Constipation (CIC) Drugs Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 45. Global Chronic Idiopathic Constipation (CIC) Drugs Sales by Region (2021-2026) & (K Units) Table 46. Global Chronic Idiopathic Constipation (CIC) Drugs Sales Market Share by Region (2021-2026) Table 47. Global Chronic Idiopathic Constipation (CIC) Drugs Sales by Region (2027-2032) & (K Units) Table 48. Global Chronic Idiopathic Constipation (CIC) Drugs Sales Market Share by Region (2027-2032) Table 49. Global Chronic Idiopathic Constipation (CIC) Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 50. Global Chronic Idiopathic Constipation (CIC) Drugs Sales Value by Region (2021-2026) & (US$ Million) Table 51. Global Chronic Idiopathic Constipation (CIC) Drugs Sales Value Share by Region (2021-2026) Table 52. Global Chronic Idiopathic Constipation (CIC) Drugs Sales Value by Region (2027-2032) & (US$ Million) Table 53. Global Chronic Idiopathic Constipation (CIC) Drugs Sales Value Share by Region (2027-2032) Table 54. Global Chronic Idiopathic Constipation (CIC) Drugs Market Average Price (US$/Unit) by Region (2021-2026) Table 55. Global Chronic Idiopathic Constipation (CIC) Drugs Market Average Price (US$/Unit) by Region (2027-2032) Table 56. Global Chronic Idiopathic Constipation (CIC) Drugs Sales by Country: 2021 VS 2025 VS 2032 (K Units) Table 57. Global Chronic Idiopathic Constipation (CIC) Drugs Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 58. Global Chronic Idiopathic Constipation (CIC) Drugs Sales by Country (2021-2026) & (K Units) Table 59. Global Chronic Idiopathic Constipation (CIC) Drugs Sales Market Share by Country (2021-2026) Table 60. Global Chronic Idiopathic Constipation (CIC) Drugs Sales by Country (2027-2032) & (K Units) Table 61. Global Chronic Idiopathic Constipation (CIC) Drugs Sales Market Share by Country (2027-2032) Table 62. Global Chronic Idiopathic Constipation (CIC) Drugs Sales Value by Country (2021-2026) & (US$ Million) Table 63. Global Chronic Idiopathic Constipation (CIC) Drugs Sales Value Market Share by Country (2021-2026) Table 64. Global Chronic Idiopathic Constipation (CIC) Drugs Sales Value by Country (2027-2032) & (US$ Million) Table 65. Global Chronic Idiopathic Constipation (CIC) Drugs Sales Value Market Share by Country (2027-2032) Table 66. Sanofi Company Information Table 67. Sanofi Business Overview Table 68. Sanofi Chronic Idiopathic Constipation (CIC) Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 69. Sanofi Chronic Idiopathic Constipation (CIC) Drugs Product Portfolio Table 70. Sanofi Recent Development Table 71. Pfizer Company Information Table 72. Pfizer Business Overview Table 73. Pfizer Chronic Idiopathic Constipation (CIC) Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 74. Pfizer Chronic Idiopathic Constipation (CIC) Drugs Product Portfolio Table 75. Pfizer Recent Development Table 76. GlaxoSmithKline Company Information Table 77. GlaxoSmithKline Business Overview Table 78. GlaxoSmithKline Chronic Idiopathic Constipation (CIC) Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 79. GlaxoSmithKline Chronic Idiopathic Constipation (CIC) Drugs Product Portfolio Table 80. GlaxoSmithKline Recent Development Table 81. Bayer Company Information Table 82. Bayer Business Overview Table 83. Bayer Chronic Idiopathic Constipation (CIC) Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 84. Bayer Chronic Idiopathic Constipation (CIC) Drugs Product Portfolio Table 85. Bayer Recent Development Table 86. Synergy Pharmaceuticals Company Information Table 87. Synergy Pharmaceuticals Business Overview Table 88. Synergy Pharmaceuticals Chronic Idiopathic Constipation (CIC) Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 89. Synergy Pharmaceuticals Chronic Idiopathic Constipation (CIC) Drugs Product Portfolio Table 90. Synergy Pharmaceuticals Recent Development Table 91. Sucampo Pharmaceuticals Company Information Table 92. Sucampo Pharmaceuticals Business Overview Table 93. Sucampo Pharmaceuticals Chronic Idiopathic Constipation (CIC) Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 94. Sucampo Pharmaceuticals Chronic Idiopathic Constipation (CIC) Drugs Product Portfolio Table 95. Sucampo Pharmaceuticals Recent Development Table 96. Salix Pharmaceuticals Company Information Table 97. Salix Pharmaceuticals Business Overview Table 98. Salix Pharmaceuticals Chronic Idiopathic Constipation (CIC) Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 99. Salix Pharmaceuticals Chronic Idiopathic Constipation (CIC) Drugs Product Portfolio Table 100. Salix Pharmaceuticals Recent Development Table 101. Roche Holding Company Information Table 102. Roche Holding Business Overview Table 103. Roche Holding Chronic Idiopathic Constipation (CIC) Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 104. Roche Holding Chronic Idiopathic Constipation (CIC) Drugs Product Portfolio Table 105. Roche Holding Recent Development Table 106. Progenics Pharmaceuticals Company Information Table 107. Progenics Pharmaceuticals Business Overview Table 108. Progenics Pharmaceuticals Chronic Idiopathic Constipation (CIC) Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 109. Progenics Pharmaceuticals Chronic Idiopathic Constipation (CIC) Drugs Product Portfolio Table 110. Progenics Pharmaceuticals Recent Development Table 111. Ironwood Pharmaceuticals Company Information Table 112. Ironwood Pharmaceuticals Business Overview Table 113. Ironwood Pharmaceuticals Chronic Idiopathic Constipation (CIC) Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 114. Ironwood Pharmaceuticals Chronic Idiopathic Constipation (CIC) Drugs Product Portfolio Table 115. Ironwood Pharmaceuticals Recent Development Table 116. Ferring International Center Company Information Table 117. Ferring International Center Business Overview Table 118. Ferring International Center Chronic Idiopathic Constipation (CIC) Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 119. Ferring International Center Chronic Idiopathic Constipation (CIC) Drugs Product Portfolio Table 120. Ferring International Center Recent Development Table 121. Chugai Pharmaceutical Company Information Table 122. Chugai Pharmaceutical Business Overview Table 123. Chugai Pharmaceutical Chronic Idiopathic Constipation (CIC) Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 124. Chugai Pharmaceutical Chronic Idiopathic Constipation (CIC) Drugs Product Portfolio Table 125. Chugai Pharmaceutical Recent Development Table 126. Actavis Company Information Table 127. Actavis Business Overview Table 128. Actavis Chronic Idiopathic Constipation (CIC) Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 129. Actavis Chronic Idiopathic Constipation (CIC) Drugs Product Portfolio Table 130. Actavis Recent Development Table 131. Key Raw Materials Table 132. Raw Materials Key Suppliers Table 133. Chronic Idiopathic Constipation (CIC) Drugs Distributors List Table 134. Chronic Idiopathic Constipation (CIC) Drugs Customers List Table 135. Research Programs/Design for This Report Table 136. Authors List of This Report Table 137. Secondary Sources Table 138. Primary Sources List of Figures Figure 1. Chronic Idiopathic Constipation (CIC) Drugs Product Image Figure 2. Global Chronic Idiopathic Constipation (CIC) Drugs Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Chronic Idiopathic Constipation (CIC) Drugs Sales Value (2021-2032) & (US$ Million) Figure 4. Global Chronic Idiopathic Constipation (CIC) Drugs Sales (2021-2032) & (K Units) Figure 5. Global Chronic Idiopathic Constipation (CIC) Drugs Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Chronic Idiopathic Constipation (CIC) Drugs Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Lubiprostone Image Figure 10. Linaclotide Image Figure 11. Others Image Figure 12. Global Chronic Idiopathic Constipation (CIC) Drugs Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units) Figure 13. Global Chronic Idiopathic Constipation (CIC) Drugs Sales Volume Share 2021 VS 2025 VS 2032 Figure 14. Global Chronic Idiopathic Constipation (CIC) Drugs Sales Volume Share by Type (2021-2032) Figure 15. Global Chronic Idiopathic Constipation (CIC) Drugs Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 16. Global Chronic Idiopathic Constipation (CIC) Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 17. Global Chronic Idiopathic Constipation (CIC) Drugs Sales Value Share by Type (2021-2032) Figure 18. Ambulatory Surgical Centres Image Figure 19. Hospitals & Clinics Image Figure 20. Long Term Care Centres Image Figure 21. Others Image Figure 22. Global Chronic Idiopathic Constipation (CIC) Drugs Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units) Figure 23. Global Chronic Idiopathic Constipation (CIC) Drugs Sales Volume Share 2021 VS 2025 VS 2032 Figure 24. Global Chronic Idiopathic Constipation (CIC) Drugs Sales Volume Share by Application (2021-2032) Figure 25. Global Chronic Idiopathic Constipation (CIC) Drugs Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 26. Global Chronic Idiopathic Constipation (CIC) Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 27. Global Chronic Idiopathic Constipation (CIC) Drugs Sales Value Share by Application (2021-2032) Figure 28. Global Chronic Idiopathic Constipation (CIC) Drugs Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 29. Global Chronic Idiopathic Constipation (CIC) Drugs Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 30. Global Chronic Idiopathic Constipation (CIC) Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 31. Global Chronic Idiopathic Constipation (CIC) Drugs Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 32. North America Chronic Idiopathic Constipation (CIC) Drugs Sales Value (2021-2032) & (US$ Million) Figure 33. North America Chronic Idiopathic Constipation (CIC) Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 34. Europe Chronic Idiopathic Constipation (CIC) Drugs Sales Value (2021-2032) & (US$ Million) Figure 35. Europe Chronic Idiopathic Constipation (CIC) Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 36. Asia-Pacific Chronic Idiopathic Constipation (CIC) Drugs Sales Value (2021-2032) & (US$ Million) Figure 37. Asia-Pacific Chronic Idiopathic Constipation (CIC) Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 38. South America Chronic Idiopathic Constipation (CIC) Drugs Sales Value (2021-2032) & (US$ Million) Figure 39. South America Chronic Idiopathic Constipation (CIC) Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 40. Middle East & Africa Chronic Idiopathic Constipation (CIC) Drugs Sales Value (2021-2032) & (US$ Million) Figure 41. Middle East & Africa Chronic Idiopathic Constipation (CIC) Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 42. USA Chronic Idiopathic Constipation (CIC) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. USA Chronic Idiopathic Constipation (CIC) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. USA Chronic Idiopathic Constipation (CIC) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. Canada Chronic Idiopathic Constipation (CIC) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. Canada Chronic Idiopathic Constipation (CIC) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. Canada Chronic Idiopathic Constipation (CIC) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Mexico Chronic Idiopathic Constipation (CIC) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Mexico Chronic Idiopathic Constipation (CIC) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Mexico Chronic Idiopathic Constipation (CIC) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Germany Chronic Idiopathic Constipation (CIC) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Germany Chronic Idiopathic Constipation (CIC) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Germany Chronic Idiopathic Constipation (CIC) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. France Chronic Idiopathic Constipation (CIC) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. France Chronic Idiopathic Constipation (CIC) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. France Chronic Idiopathic Constipation (CIC) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. U.K. Chronic Idiopathic Constipation (CIC) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. U.K. Chronic Idiopathic Constipation (CIC) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. U.K. Chronic Idiopathic Constipation (CIC) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Italy Chronic Idiopathic Constipation (CIC) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Italy Chronic Idiopathic Constipation (CIC) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Italy Chronic Idiopathic Constipation (CIC) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Spain Chronic Idiopathic Constipation (CIC) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Spain Chronic Idiopathic Constipation (CIC) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Spain Chronic Idiopathic Constipation (CIC) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Russia Chronic Idiopathic Constipation (CIC) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Russia Chronic Idiopathic Constipation (CIC) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Russia Chronic Idiopathic Constipation (CIC) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Netherlands Chronic Idiopathic Constipation (CIC) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Netherlands Chronic Idiopathic Constipation (CIC) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Netherlands Chronic Idiopathic Constipation (CIC) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. Nordic Countries Chronic Idiopathic Constipation (CIC) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. Nordic Countries Chronic Idiopathic Constipation (CIC) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. Nordic Countries Chronic Idiopathic Constipation (CIC) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. China Chronic Idiopathic Constipation (CIC) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. China Chronic Idiopathic Constipation (CIC) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. China Chronic Idiopathic Constipation (CIC) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Japan Chronic Idiopathic Constipation (CIC) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Japan Chronic Idiopathic Constipation (CIC) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Japan Chronic Idiopathic Constipation (CIC) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. South Korea Chronic Idiopathic Constipation (CIC) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. South Korea Chronic Idiopathic Constipation (CIC) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. South Korea Chronic Idiopathic Constipation (CIC) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. India Chronic Idiopathic Constipation (CIC) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. India Chronic Idiopathic Constipation (CIC) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. India Chronic Idiopathic Constipation (CIC) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Australia Chronic Idiopathic Constipation (CIC) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Australia Chronic Idiopathic Constipation (CIC) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Australia Chronic Idiopathic Constipation (CIC) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Southeast Asia Chronic Idiopathic Constipation (CIC) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Southeast Asia Chronic Idiopathic Constipation (CIC) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Southeast Asia Chronic Idiopathic Constipation (CIC) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Brazil Chronic Idiopathic Constipation (CIC) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Brazil Chronic Idiopathic Constipation (CIC) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Brazil Chronic Idiopathic Constipation (CIC) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Argentina Chronic Idiopathic Constipation (CIC) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Argentina Chronic Idiopathic Constipation (CIC) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Argentina Chronic Idiopathic Constipation (CIC) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Chile Chronic Idiopathic Constipation (CIC) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Chile Chronic Idiopathic Constipation (CIC) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Chile Chronic Idiopathic Constipation (CIC) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Colombia Chronic Idiopathic Constipation (CIC) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Colombia Chronic Idiopathic Constipation (CIC) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Colombia Chronic Idiopathic Constipation (CIC) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Peru Chronic Idiopathic Constipation (CIC) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Peru Chronic Idiopathic Constipation (CIC) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Peru Chronic Idiopathic Constipation (CIC) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Saudi Arabia Chronic Idiopathic Constipation (CIC) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Saudi Arabia Chronic Idiopathic Constipation (CIC) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Saudi Arabia Chronic Idiopathic Constipation (CIC) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Israel Chronic Idiopathic Constipation (CIC) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Israel Arabia Chronic Idiopathic Constipation (CIC) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Israel Arabia Chronic Idiopathic Constipation (CIC) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. UAE Chronic Idiopathic Constipation (CIC) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. UAE Chronic Idiopathic Constipation (CIC) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. UAE Chronic Idiopathic Constipation (CIC) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. Turkey Chronic Idiopathic Constipation (CIC) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 118. Turkey Chronic Idiopathic Constipation (CIC) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 119. Turkey Chronic Idiopathic Constipation (CIC) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 120. Iran Chronic Idiopathic Constipation (CIC) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 121. Iran Chronic Idiopathic Constipation (CIC) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 122. Iran Chronic Idiopathic Constipation (CIC) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 123. Egypt Chronic Idiopathic Constipation (CIC) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 124. Egypt Chronic Idiopathic Constipation (CIC) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 125. Egypt Chronic Idiopathic Constipation (CIC) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 126. Chronic Idiopathic Constipation (CIC) Drugs Value Chain Figure 127. Manufacturing Cost Structure Figure 128. Chronic Idiopathic Constipation (CIC) Drugs Sales Mode & Process Figure 129. Direct Comparison with Distribution Share Figure 130. Distributors Profiles Figure 131. Years Considered Figure 132. Research Process Figure 133. Key Executives Interviewed

Scope & coverage.

Types
  • Lubiprostone
  • Linaclotide
  • Others
Applications
  • Ambulatory Surgical Centres
  • Hospitals & Clinics
  • Long Term Care Centres
  • Others
Companies covered
  • Sanofi
  • Pfizer
  • GlaxoSmithKline
  • Bayer
  • Synergy Pharmaceuticals
  • Sucampo Pharmaceuticals
  • Salix Pharmaceuticals
  • Roche Holding
  • Progenics Pharmaceuticals
  • Ironwood Pharmaceuticals
  • Ferring International Center
  • Chugai Pharmaceutical
  • Actavis

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Chronic Idiopathic Constipation (CIC) Drugs Sales Value (2021-2032)
  4. 1.2.2 Global Chronic Idiopathic Constipation (CIC) Drugs Sales Volume (2021-2032)
  5. 1.2.3 Global Chronic Idiopathic Constipation (CIC) Drugs Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Chronic Idiopathic Constipation (CIC) Drugs Market Dynamics
  1. 2.1 Chronic Idiopathic Constipation (CIC) Drugs Industry Trends
  2. 2.2 Chronic Idiopathic Constipation (CIC) Drugs Industry Drivers
  3. 2.3 Chronic Idiopathic Constipation (CIC) Drugs Industry Opportunities and Challenges
  4. 2.4 Chronic Idiopathic Constipation (CIC) Drugs Industry Restraints
3 Chronic Idiopathic Constipation (CIC) Drugs Market by Company
  1. 3.1 Global Chronic Idiopathic Constipation (CIC) Drugs Company Revenue Ranking in 2025
  2. 3.2 Global Chronic Idiopathic Constipation (CIC) Drugs Revenue by Company (2021-2026)
  3. 3.3 Global Chronic Idiopathic Constipation (CIC) Drugs Sales Volume by Company (2021-2026)
  4. 3.4 Global Chronic Idiopathic Constipation (CIC) Drugs Average Price by Company (2021-2026)
  5. 3.5 Global Chronic Idiopathic Constipation (CIC) Drugs Company Ranking (2024-2026)
  6. 3.6 Global Chronic Idiopathic Constipation (CIC) Drugs Company Manufacturing Base and Headquarters
  7. 3.7 Global Chronic Idiopathic Constipation (CIC) Drugs Company Product Type and Application
  8. 3.8 Global Chronic Idiopathic Constipation (CIC) Drugs Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Chronic Idiopathic Constipation (CIC) Drugs Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Chronic Idiopathic Constipation (CIC) Drugs Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Chronic Idiopathic Constipation (CIC) Drugs Market by Type
  1. 4.1 Chronic Idiopathic Constipation (CIC) Drugs Type Introduction
  2. 4.1.1 Lubiprostone
  3. 4.1.2 Linaclotide
  4. 4.1.3 Others
  5. 4.2 Global Chronic Idiopathic Constipation (CIC) Drugs Sales Volume by Type
  6. 4.2.1 Global Chronic Idiopathic Constipation (CIC) Drugs Sales Volume by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Chronic Idiopathic Constipation (CIC) Drugs Sales Volume by Type (2021-2032)
  8. 4.2.3 Global Chronic Idiopathic Constipation (CIC) Drugs Sales Volume Share by Type (2021-2032)
  9. 4.3 Global Chronic Idiopathic Constipation (CIC) Drugs Sales Value by Type
  10. 4.3.1 Global Chronic Idiopathic Constipation (CIC) Drugs Sales Value by Type (2021 VS 2025 VS 2032)
  11. 4.3.2 Global Chronic Idiopathic Constipation (CIC) Drugs Sales Value by Type (2021-2032)
  12. 4.3.3 Global Chronic Idiopathic Constipation (CIC) Drugs Sales Value Share by Type (2021-2032)
5 Chronic Idiopathic Constipation (CIC) Drugs Market by Application
  1. 5.1 Chronic Idiopathic Constipation (CIC) Drugs Application Introduction
  2. 5.1.1 Ambulatory Surgical Centres
  3. 5.1.2 Hospitals & Clinics
  4. 5.1.3 Long Term Care Centres
  5. 5.1.4 Others
  6. 5.2 Global Chronic Idiopathic Constipation (CIC) Drugs Sales Volume by Application
  7. 5.2.1 Global Chronic Idiopathic Constipation (CIC) Drugs Sales Volume by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global Chronic Idiopathic Constipation (CIC) Drugs Sales Volume by Application (2021-2032)
  9. 5.2.3 Global Chronic Idiopathic Constipation (CIC) Drugs Sales Volume Share by Application (2021-2032)
  10. 5.3 Global Chronic Idiopathic Constipation (CIC) Drugs Sales Value by Application
  11. 5.3.1 Global Chronic Idiopathic Constipation (CIC) Drugs Sales Value by Application (2021 VS 2025 VS 2032)
  12. 5.3.2 Global Chronic Idiopathic Constipation (CIC) Drugs Sales Value by Application (2021-2032)
  13. 5.3.3 Global Chronic Idiopathic Constipation (CIC) Drugs Sales Value Share by Application (2021-2032)
6 Chronic Idiopathic Constipation (CIC) Drugs Regional Sales and Value Analysis
  1. 6.1 Global Chronic Idiopathic Constipation (CIC) Drugs Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Chronic Idiopathic Constipation (CIC) Drugs Sales by Region (2021-2032)
  3. 6.2.1 Global Chronic Idiopathic Constipation (CIC) Drugs Sales by Region: 2021-2026
  4. 6.2.2 Global Chronic Idiopathic Constipation (CIC) Drugs Sales by Region (2027-2032)
  5. 6.3 Global Chronic Idiopathic Constipation (CIC) Drugs Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Chronic Idiopathic Constipation (CIC) Drugs Sales Value by Region (2021-2032)
  7. 6.4.1 Global Chronic Idiopathic Constipation (CIC) Drugs Sales Value by Region: 2021-2026
  8. 6.4.2 Global Chronic Idiopathic Constipation (CIC) Drugs Sales Value by Region (2027-2032)
  9. 6.5 Global Chronic Idiopathic Constipation (CIC) Drugs Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Chronic Idiopathic Constipation (CIC) Drugs Sales Value (2021-2032)
  12. 6.6.2 North America Chronic Idiopathic Constipation (CIC) Drugs Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Chronic Idiopathic Constipation (CIC) Drugs Sales Value (2021-2032)
  15. 6.7.2 Europe Chronic Idiopathic Constipation (CIC) Drugs Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Chronic Idiopathic Constipation (CIC) Drugs Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Chronic Idiopathic Constipation (CIC) Drugs Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Chronic Idiopathic Constipation (CIC) Drugs Sales Value (2021-2032)
  21. 6.9.2 South America Chronic Idiopathic Constipation (CIC) Drugs Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Chronic Idiopathic Constipation (CIC) Drugs Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Chronic Idiopathic Constipation (CIC) Drugs Sales Value Share by Country, 2025 VS 2032
7 Chronic Idiopathic Constipation (CIC) Drugs Country-level Sales and Value Analysis
  1. 7.1 Global Chronic Idiopathic Constipation (CIC) Drugs Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Chronic Idiopathic Constipation (CIC) Drugs Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Chronic Idiopathic Constipation (CIC) Drugs Sales by Country (2021-2032)
  4. 7.3.1 Global Chronic Idiopathic Constipation (CIC) Drugs Sales by Country (2021-2026)
  5. 7.3.2 Global Chronic Idiopathic Constipation (CIC) Drugs Sales by Country (2027-2032)
  6. 7.4 Global Chronic Idiopathic Constipation (CIC) Drugs Sales Value by Country (2021-2032)
  7. 7.4.1 Global Chronic Idiopathic Constipation (CIC) Drugs Sales Value by Country (2021-2026)
  8. 7.4.2 Global Chronic Idiopathic Constipation (CIC) Drugs Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Chronic Idiopathic Constipation (CIC) Drugs Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Chronic Idiopathic Constipation (CIC) Drugs Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Chronic Idiopathic Constipation (CIC) Drugs Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Chronic Idiopathic Constipation (CIC) Drugs Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Chronic Idiopathic Constipation (CIC) Drugs Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Chronic Idiopathic Constipation (CIC) Drugs Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Chronic Idiopathic Constipation (CIC) Drugs Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Chronic Idiopathic Constipation (CIC) Drugs Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Chronic Idiopathic Constipation (CIC) Drugs Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Chronic Idiopathic Constipation (CIC) Drugs Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Chronic Idiopathic Constipation (CIC) Drugs Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Chronic Idiopathic Constipation (CIC) Drugs Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Chronic Idiopathic Constipation (CIC) Drugs Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Chronic Idiopathic Constipation (CIC) Drugs Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Chronic Idiopathic Constipation (CIC) Drugs Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Chronic Idiopathic Constipation (CIC) Drugs Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Chronic Idiopathic Constipation (CIC) Drugs Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Chronic Idiopathic Constipation (CIC) Drugs Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Chronic Idiopathic Constipation (CIC) Drugs Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Chronic Idiopathic Constipation (CIC) Drugs Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Chronic Idiopathic Constipation (CIC) Drugs Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Chronic Idiopathic Constipation (CIC) Drugs Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Chronic Idiopathic Constipation (CIC) Drugs Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Chronic Idiopathic Constipation (CIC) Drugs Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Chronic Idiopathic Constipation (CIC) Drugs Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Chronic Idiopathic Constipation (CIC) Drugs Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Chronic Idiopathic Constipation (CIC) Drugs Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Chronic Idiopathic Constipation (CIC) Drugs Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Chronic Idiopathic Constipation (CIC) Drugs Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Chronic Idiopathic Constipation (CIC) Drugs Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Chronic Idiopathic Constipation (CIC) Drugs Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Chronic Idiopathic Constipation (CIC) Drugs Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Chronic Idiopathic Constipation (CIC) Drugs Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Chronic Idiopathic Constipation (CIC) Drugs Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Chronic Idiopathic Constipation (CIC) Drugs Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Chronic Idiopathic Constipation (CIC) Drugs Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Chronic Idiopathic Constipation (CIC) Drugs Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Chronic Idiopathic Constipation (CIC) Drugs Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Chronic Idiopathic Constipation (CIC) Drugs Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Chronic Idiopathic Constipation (CIC) Drugs Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Chronic Idiopathic Constipation (CIC) Drugs Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Chronic Idiopathic Constipation (CIC) Drugs Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Chronic Idiopathic Constipation (CIC) Drugs Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Chronic Idiopathic Constipation (CIC) Drugs Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Chronic Idiopathic Constipation (CIC) Drugs Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Chronic Idiopathic Constipation (CIC) Drugs Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Chronic Idiopathic Constipation (CIC) Drugs Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Chronic Idiopathic Constipation (CIC) Drugs Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Chronic Idiopathic Constipation (CIC) Drugs Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Chronic Idiopathic Constipation (CIC) Drugs Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Chronic Idiopathic Constipation (CIC) Drugs Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Chronic Idiopathic Constipation (CIC) Drugs Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Chronic Idiopathic Constipation (CIC) Drugs Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Chronic Idiopathic Constipation (CIC) Drugs Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Chronic Idiopathic Constipation (CIC) Drugs Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Chronic Idiopathic Constipation (CIC) Drugs Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Chronic Idiopathic Constipation (CIC) Drugs Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Chronic Idiopathic Constipation (CIC) Drugs Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Chronic Idiopathic Constipation (CIC) Drugs Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Chronic Idiopathic Constipation (CIC) Drugs Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Chronic Idiopathic Constipation (CIC) Drugs Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Chronic Idiopathic Constipation (CIC) Drugs Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Chronic Idiopathic Constipation (CIC) Drugs Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Chronic Idiopathic Constipation (CIC) Drugs Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Chronic Idiopathic Constipation (CIC) Drugs Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Chronic Idiopathic Constipation (CIC) Drugs Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Chronic Idiopathic Constipation (CIC) Drugs Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Chronic Idiopathic Constipation (CIC) Drugs Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Chronic Idiopathic Constipation (CIC) Drugs Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Chronic Idiopathic Constipation (CIC) Drugs Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Chronic Idiopathic Constipation (CIC) Drugs Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Chronic Idiopathic Constipation (CIC) Drugs Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Chronic Idiopathic Constipation (CIC) Drugs Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Chronic Idiopathic Constipation (CIC) Drugs Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Chronic Idiopathic Constipation (CIC) Drugs Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Chronic Idiopathic Constipation (CIC) Drugs Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Chronic Idiopathic Constipation (CIC) Drugs Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Chronic Idiopathic Constipation (CIC) Drugs Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Chronic Idiopathic Constipation (CIC) Drugs Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Chronic Idiopathic Constipation (CIC) Drugs Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Chronic Idiopathic Constipation (CIC) Drugs Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Chronic Idiopathic Constipation (CIC) Drugs Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Chronic Idiopathic Constipation (CIC) Drugs Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Chronic Idiopathic Constipation (CIC) Drugs Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Sanofi
  2. 8.1.1 Sanofi Company Information
  3. 8.1.2 Sanofi Business Overview
  4. 8.1.3 Sanofi Chronic Idiopathic Constipation (CIC) Drugs Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Sanofi Chronic Idiopathic Constipation (CIC) Drugs Product Portfolio
  6. 8.1.5 Sanofi Recent Developments
  7. 8.2 Pfizer
  8. 8.2.1 Pfizer Company Information
  9. 8.2.2 Pfizer Business Overview
  10. 8.2.3 Pfizer Chronic Idiopathic Constipation (CIC) Drugs Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Pfizer Chronic Idiopathic Constipation (CIC) Drugs Product Portfolio
  12. 8.2.5 Pfizer Recent Developments
  13. 8.3 GlaxoSmithKline
  14. 8.3.1 GlaxoSmithKline Company Information
  15. 8.3.2 GlaxoSmithKline Business Overview
  16. 8.3.3 GlaxoSmithKline Chronic Idiopathic Constipation (CIC) Drugs Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 GlaxoSmithKline Chronic Idiopathic Constipation (CIC) Drugs Product Portfolio
  18. 8.3.5 GlaxoSmithKline Recent Developments
  19. 8.4 Bayer
  20. 8.4.1 Bayer Company Information
  21. 8.4.2 Bayer Business Overview
  22. 8.4.3 Bayer Chronic Idiopathic Constipation (CIC) Drugs Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Bayer Chronic Idiopathic Constipation (CIC) Drugs Product Portfolio
  24. 8.4.5 Bayer Recent Developments
  25. 8.5 Synergy Pharmaceuticals
  26. 8.5.1 Synergy Pharmaceuticals Company Information
  27. 8.5.2 Synergy Pharmaceuticals Business Overview
  28. 8.5.3 Synergy Pharmaceuticals Chronic Idiopathic Constipation (CIC) Drugs Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Synergy Pharmaceuticals Chronic Idiopathic Constipation (CIC) Drugs Product Portfolio
  30. 8.5.5 Synergy Pharmaceuticals Recent Developments
  31. 8.6 Sucampo Pharmaceuticals
  32. 8.6.1 Sucampo Pharmaceuticals Company Information
  33. 8.6.2 Sucampo Pharmaceuticals Business Overview
  34. 8.6.3 Sucampo Pharmaceuticals Chronic Idiopathic Constipation (CIC) Drugs Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Sucampo Pharmaceuticals Chronic Idiopathic Constipation (CIC) Drugs Product Portfolio
  36. 8.6.5 Sucampo Pharmaceuticals Recent Developments
  37. 8.7 Salix Pharmaceuticals
  38. 8.7.1 Salix Pharmaceuticals Company Information
  39. 8.7.2 Salix Pharmaceuticals Business Overview
  40. 8.7.3 Salix Pharmaceuticals Chronic Idiopathic Constipation (CIC) Drugs Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Salix Pharmaceuticals Chronic Idiopathic Constipation (CIC) Drugs Product Portfolio
  42. 8.7.5 Salix Pharmaceuticals Recent Developments
  43. 8.8 Roche Holding
  44. 8.8.1 Roche Holding Company Information
  45. 8.8.2 Roche Holding Business Overview
  46. 8.8.3 Roche Holding Chronic Idiopathic Constipation (CIC) Drugs Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Roche Holding Chronic Idiopathic Constipation (CIC) Drugs Product Portfolio
  48. 8.8.5 Roche Holding Recent Developments
  49. 8.9 Progenics Pharmaceuticals
  50. 8.9.1 Progenics Pharmaceuticals Company Information
  51. 8.9.2 Progenics Pharmaceuticals Business Overview
  52. 8.9.3 Progenics Pharmaceuticals Chronic Idiopathic Constipation (CIC) Drugs Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Progenics Pharmaceuticals Chronic Idiopathic Constipation (CIC) Drugs Product Portfolio
  54. 8.9.5 Progenics Pharmaceuticals Recent Developments
  55. 8.10 Ironwood Pharmaceuticals
  56. 8.10.1 Ironwood Pharmaceuticals Company Information
  57. 8.10.2 Ironwood Pharmaceuticals Business Overview
  58. 8.10.3 Ironwood Pharmaceuticals Chronic Idiopathic Constipation (CIC) Drugs Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Ironwood Pharmaceuticals Chronic Idiopathic Constipation (CIC) Drugs Product Portfolio
  60. 8.10.5 Ironwood Pharmaceuticals Recent Developments
  61. 8.11 Ferring International Center
  62. 8.11.1 Ferring International Center Company Information
  63. 8.11.2 Ferring International Center Business Overview
  64. 8.11.3 Ferring International Center Chronic Idiopathic Constipation (CIC) Drugs Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 Ferring International Center Chronic Idiopathic Constipation (CIC) Drugs Product Portfolio
  66. 8.11.5 Ferring International Center Recent Developments
  67. 8.12 Chugai Pharmaceutical
  68. 8.12.1 Chugai Pharmaceutical Company Information
  69. 8.12.2 Chugai Pharmaceutical Business Overview
  70. 8.12.3 Chugai Pharmaceutical Chronic Idiopathic Constipation (CIC) Drugs Sales, Value and Gross Margin (2021-2026)
  71. 8.12.4 Chugai Pharmaceutical Chronic Idiopathic Constipation (CIC) Drugs Product Portfolio
  72. 8.12.5 Chugai Pharmaceutical Recent Developments
  73. 8.13 Actavis
  74. 8.13.1 Actavis Company Information
  75. 8.13.2 Actavis Business Overview
  76. 8.13.3 Actavis Chronic Idiopathic Constipation (CIC) Drugs Sales, Value and Gross Margin (2021-2026)
  77. 8.13.4 Actavis Chronic Idiopathic Constipation (CIC) Drugs Product Portfolio
  78. 8.13.5 Actavis Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Chronic Idiopathic Constipation (CIC) Drugs Value Chain Analysis
  2. 9.1.1 Chronic Idiopathic Constipation (CIC) Drugs Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Chronic Idiopathic Constipation (CIC) Drugs Sales Mode & Process
  6. 9.2 Chronic Idiopathic Constipation (CIC) Drugs Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Chronic Idiopathic Constipation (CIC) Drugs Distributors
  9. 9.2.3 Chronic Idiopathic Constipation (CIC) Drugs Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst